EST DexCom (DXCM) falls 7% to $71.99 after receiving warning letter from FDADiscover the Best Stocks and Maximize Your Portfolio: See ...

Dexcom was issued with an FDA warning letter after issues with “manufacturing processes and quality management systems.” ...

Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following ...

Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

DexCom (NasdaqGS:DXCM) recently received a warning letter from the FDA, which pointed out issues in manufacturing processes and quality management. While these regulatory developments did not impact ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Dexcom announced today that it received a warning letter from the FDA following inspections of two company facilities.

DexCom's growth is slowing with 2024 marking the slowest growth year in a decade and 2025 expected to follow suit with ~14% ...

PNC Financial Services Group Inc. raised its position in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 21.5% in the fourth ...

Shares of DexCom Inc. DXCM slid 2.10% to $77.84 Friday, on what proved to be an all-around great trading session for the ...

In a regulatory filing, DexCom (DXCM) disclosed that on March 4, the company received a warning letter from the U.S. FDA following inspections ...